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Abstract
Background: TIMI frame count (TFC) predicts outcomes in patients with obstructive coronary artery disease (CAD); it
remains unclear whether TFC predicts outcomes in patients without obstructive CAD.
Methods: TFC was determined in a sample of women with no obstructive CAD enrolled in the Women’s Ischemia Syndrome
Evaluation (WISE) study. Because TFC is known to be higher in the left anterior descending artery (LAD), TFC determined in
the LAD was divided by 1.7 to provide a corrected TFC (cTFC).
Results: A total of 298 women, with angiograms suitable for TFC analysis and long-term (6–10 year) follow up data, were
included in this sub-study. Their age was 55611 years, most were white (86%), half had a history of smoking, and half had a
history of hypertension. Higher resting cTFC was associated with a higher rate of hospitalization for angina (34% in women
with a cTFC .35, 15% in women with a cTFC #35, P,0.001). cTFC provided independent prediction of hospitalization for
angina after adjusting for many baseline characteristics. In this cohort, resting cTFC was not predictive of major events
(myocardial infarction, heart failure, stroke, or all-cause death), cardiovascular events, all-cause mortality, or cardiovascular
mortality.
Conclusions: In women with signs and symptoms of ischemia but no obstructive CAD, resting cTFC provides independent
prediction of hospitalization for angina. Larger studies are required to determine if resting TFC is predictive of major events
in patients without obstructive coronary artery disease.
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Introduction
Women with symptoms and signs of ischemia, referred for
invasive coronary evaluation, often have no evidence of obstruc-
tive coronary artery disease (CAD) [1]. We and others have
identified that symptomatic patients with non-obstructive CAD
have an elevated risk of adverse outcomes and all-cause mortality
compared with cohorts without symptoms and/or signs of
ischemic heart disease [2,3]. About 45% to 60% of such patients
have coronary vascular dysregulation (endothelial or non-endo-
thelial dependent macro- or microvascular dysfunction) capable of
causing ischemia with invasive provocative testing [1,4]. Addi-
tionally, we and others have linked coronary vascular dysregula-
tion with adverse outcomes. Thus, additional indices of coronary
vasomotor function, beyond standard anatomy from angiography,
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would be useful to improve risk stratification of these patients [5–
9].
The Thrombolysis in Myocardial Infarction (TIMI) frame count
(TFC) provides a simple angiographic index of coronary blood
flow that does not require additional coronary artery instrumen-
tation [10]. The intra- and inter-observer reproducibility of TFC is
good, and dye injection rate and catheter size do not affect its
measurement [11,12]. The TFC has correlated with other invasive
and non-invasive measures of coronary blood flow [13–16].
Further, TFC estimates of coronary flow after reperfusion for
acute myocardial infarction predict short- and long-term clinical
outcomes [17–19]. However, the prognostic implication of an
abnormal TFC in patients without acute myocardial infarction or
obstructive CAD and with suspected microvascular dysfunction
remains unclear. Accordingly, we aimed to determine if TFC at
rest is predictive of adverse outcomes in patients without
obstructive CAD.
Methods
Patients
The Women’s Ischemia Syndrome Evaluation (WISE) study
(clinicaltrials.gov Identifier NCT00000554) is a National Heart,
Lung and Blood Institute–sponsored study aimed at improving
diagnostic evaluation and understanding of pathological mecha-
nisms of ischemic heart disease in women. The WISE protocol was
approved by the relevant institutional review boards (IRB)
(University of Florida IRB, Allegany General Hospital IRB,
University of Pittsburgh IRB, University of Alabama at Birming-
ham IRB), and has previously been described [20]. All participants
provided written informed consent to participate in this study. The
consent procedure and form were approved by the local IRBs
listed. Briefly, women older than 18 years of age with symptoms
and signs of ischemia undergoing clinically indicated angiograms
were followed for clinical outcomes. Major exclusion criteria
included comorbidities likely to compromise follow up. Initial
evaluation in addition to coronary angiography included collection
of demographics, medical history, symptom data, physical
examination, and blood sampling for lipids, reproductive hor-
mones, and inflammatory markers.
Coronary Angiography and TIMI frame counts
Coronary angiography was performed at the clinical sites
according to standard methods. Qualitative and quantitative
coronary angiographic analyses were conducted by a core
laboratory masked to patient data [21]. As previously described,
the TFC was determined as the number of cine frames required
for contrast to reach standardized distal coronary landmarks [10].
The first frame used for TFC is the frame in which dye fully enters
the artery of interest. The last frame that is counted is the frame
when dye enters the distal landmark branch (Figure 1). The distal
landmark branch of the left anterior descending (LAD) artery was
the distal bifurcation. In normal coronaries, the TFC in the LAD
is on average 1.7 times longer than the TFC in the other coronary
arteries. Therefore, the LAD frame counts were divided by 1.7 to
provide a corrected TFC (cTFC) [10]. Those patients who had an
angiogram recorded in a way that allowed the determination of
TFC by the core lab and were found not to have obstructive CAD
are included in this analysis.
Follow-up for adverse events
After the baseline angiogram and coronary reactivity testing, the
WISE women had protocol-directed yearly follow-up. During
telephone contact, a scripted interview was completed by an
experienced nurse or physician at the respective center. Each
patient or family member was queried for occurrence of major
adverse cardiac events or hospitalizations. Telephone follow-up
was terminated at a maximum of 8 years, with a median follow-up
of 6 years. Additionally, after the phone follow-up period, a second
phase of follow-up was performed with a search of the National
Death Index for those patients still alive at last contact who had
not withdrawn consent. This extended the follow-up for mortality
to approximately 10 years. In the event of death, a death
certificate and/or physician narrative was obtained. All deaths
were adjudicated as cardiovascular (CV) or non-CV by a
committee of senior WISE investigators blinded to angiographic
findings. Women sustaining multiple events were counted only
once and by the initial event.
Statistical Analysis
Baseline characteristics are described by mean and standard
deviation for continuous variables and percentages for categorical
variables. The Kaplan-Meier method was used to estimate 10-year
CV events rates by tertiles of cTFC, and compared by use of the
log-rank statistic. To determine the cTFC cutpoint for predicting
hospitalization for angina, we generated a receiver-operator
characteristic (ROC) curve using logistic regression. The cTFC
value corresponding to the point of the curve closest to 100%
sensitivity and specificity was selected and verified in subsequent
runs of incremental cut-points near that value. Multivariate Cox
proportional hazards regression was used to examine the
relationship between baseline characteristics and adverse out-
comes. Baseline characteristics were chosen for entry into
multivariable Cox models on the basis of their discrimination
between those patients above and below the optimal cTFC
cutpoint, as well as on univariate associations with adverse
outcomes of P,0.20. A combination of forward and backward
selection procedures were used to aid in determining the best
model of independent predictors. This was followed by forcing
potential confounders into the models and determining their effect
on the relationship of interest. The likelihood ratio test was used to
compare the incremental goodness of fit of nested models. All tests
were 2-sided, and P#0.05 was considered statistically significant.
All analyses were performed with SAS software version 9.3 (SAS
Institute). Sample Size Considerations. Using previously published data
for women in the WISE with non-obstructive coronary disease [9],
we assumed a reference 6-year event-free survival rate of 91% for
such women without coronary microvascular dysfunction (e.g.
normal cTFC). Event-free survival was taken as freedom from first
occurrence of death (all-cause), nonfatal MI, non-fatal stroke, or
hospitalization for heart failure. We assumed that women with
abnormal coronary microvascular function (e.g. high cTFC) would
have reduced event-free survival. This was expressed as a hazard
ratio of 2.5 (corresponding to a 6-year event free survival rate of
approximately 79%) with proportional hazard assumption.
Assuming 5% censoring, we would need 300 women to achieve
80% power and need 500 women to achieve 95% power, using a
two-sided log-rank test with alpha level of 0.05. SAS procedure
PROC POWER was used to perform the power analysis. We
suspected we were underpowered in our comparison of the
incidence of the binary outcome of major events between TFC
groups, and we used the Kaplan-Meier estimated rates of major
events between our two TFC groups in this pilot study (20% vs.
13%) to determine the sample size necessary to detect a statistically
significant difference at a power of 80% and an alpha of 0.05 using
the SAS procedure PROC POWER with two-sided Pearson’s chi
square test.
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Results
Baseline Characteristics
We report on a subgroup of 298 women without obstructive
CAD (no stenosis $50% diameter reduction), whose angiograms
could be retrieved and were suitable for analysis by TFC, and for
whom clinical outcome data were available. Their baseline
demographics are shown in Table 1. Their mean age was
55611 years, most were white (86%), nearly half had a history of
smoking, and half had a history of hypertension.
Angiography and TFC
These women, in aggregate, had normal overall left ventricular
systolic function with a mean ejection fraction of 66610%. The
mean cTFC was 33.9610.0 with a range of 18 to 91.
Adverse Outcomes
Adverse event rates were compared between patients in the
various cTFC tertiles (cTFC #28, 29–37, and .37). During a
median follow up of 6 years, the Kaplan-Meier event rate for
angina hospitalization was highest for those women in the highest
cTFC tertile (35%, vs. 24% in the middle cTFC tertile, and 19%
in the lowest cTFC tertile, P = 0.022). However, the rates of major
events (myocardial infarction, heart failure, stroke, or all-cause
death), CV events (myocardial infarction, heart failure, stroke, or
CV death), all-cause mortality, or CV mortality were not
statistically different between women in the various cTFC tertiles.
By ROC analysis, a cTFC of .35 provided the best cut-point
for predicting hospitalization for angina, with a sensitivity of 61%
and a specificity of 66%. The area under the curve was 0.63 (95%
confidence interval [CI] 0.57 to 0.7). Adverse event rates in those
patients above versus at or below a cTFC of 35 are shown in
Table 2. Thirty four percent of women with a cTFC .35 were
hospitalized for angina, whereas only 15% of women with a cTFC
#35 were hospitalized for angina (P,0.001) (Figure 2).
Baseline characteristics were examined for their prediction of
hospitalization for angina. Patients with white race had a lower
risk of hospitalization for angina (age-adjusted HR=0.43 [95% CI
0.24, 0.76], P= 0.004), whereas a history of unstable angina in the
preceding 6 weeks predicted hospitalization for angina (age-
adjusted HR 1.79 [95% CI 1.05, 3.03], P= 0.03). Further, the use
of various medications at baseline was predictive of angina
hospitalization: anti-hypertensives (age-adjusted HR 1.96 [95% CI
1.15, 3.35], P= 0.014); ACE inhibitors (age-adjusted HR 2.17
[95% CI 1.22, 3.86], P= 0.009); and diuretics (age-adjusted HR
2.09 [95% CI 1.2, 3.62], P= 0.009).
When added to a predictive model that included cTFC at cut-
point 35, a history of unstable angina and diuretic use were not
independently associated with hospitalization for angina. In
contrast, when white race was included in a model that contained
cTFC at cut-point 35, it did provide an independent predictor of
lower risk of hospitalization for angina (HR 0.53 [95% CI 0.3,
0.94], P= 0.03). Additionally, when ACE inhibitor use was
included in a model that contained cTFC at cut-point 35, it was
associated with a higher risk of hospitalization for angina (HR 2.04
[95% CI 1.15, 3.59], P= 0.014). However, when ACE inhibitor
use, white race, and cTFC at cut-point 35 were all included in a
predictive model of hospitalization for angina, only cTFC
provided independent prediction of hospitalization for angina.
Discussion
Microvascular coronary dysfunction is prevalent in patients
presenting with chest pain who have no evidence of obstructive
CAD on standard angiography, and is associated with adverse
outcomes. Microvascular coronary dysfunction is commonly
diagnosed by evaluating coronary blood flow before and after
administration of adenosine with a Doppler-tipped guide wire in
the coronary. TFC does not require placement of a wire in the
coronary artery, and has been shown to correlate with coronary
blood flow and prognosis in patients with acute coronary events.
The correlation of TFC with adverse outcomes in patients with no
obstructive disease but suspected microvascular coronary dysfunc-
tion is less clear.
In the 298 women included in this study who had chest pain but
no evidence of obstructive CAD, a high cTFC was associated with
an increased risk of hospitalization for angina. Moreover, a high
cTFC remained the strongest predictor of hospitalization for
angina after controlling for baseline characteristics. Interestingly,
ACE inhibitor use was also associated with an increased risk of
angina hospitalization. We have previously shown that patients
randomized to an ACE inhibitor had greater improvement in
angina severity as compared to those who received placebo [22].
So these data are biased by WISE investigators likely prescribing
Figure 1. TIMI Frame Count. The first frame used to determine the TIMI Frame Count is the frame in which dye fully enters the artery of interest
(left, arrow). The last frame that is counted is the frame when dye enters the distal landmark branch (right, arrow).
doi:10.1371/journal.pone.0096630.g001
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Table 1. Baseline characteristics and risk factors.
Characteristic
All women
(n=298)
cTFC #35
n=179
cTFC .35
n=119
P (unad-
justed) P (age-adjusted)
Demographics
Age (y) 55611 56611 54610 0.20 -
Postmenopausal (%)** 210/296 (71) 72 69 0.53 -
White race (%) 257 (86) 90 80 0.009 0.013
HS educ. or more (%) 243/294 (83) 82 83 0.97 0.94
Body size
Waist circumference (in) 36.866.8 36.065.5 38.268.5 0.027 0.020
BMI 30.367.1 29.866.6 31.067.8 0.17 0.20
Waist/hip ratio 0.8560.12 0.8560.11 0.8760.14 0.20 0.18
Self-reported risk factors
Hx diabetes (%) 42/297 (14) 11 19 0.07 0.053
Family hx of CAD (%) 181/290 (62) 59 67 0.16 0.18
Hx hypertension (%) 143/296 (48) 47 51 0.48 0.34
Hx dyslipidemia (%) 116/275 (42) 43 40 0.65 0.74
Ever smoker (%) 151/297 (51) 54 47 0.24 0.20
Current smoker (%) 58/297 (20) 20 19 0.75 0.50
High stress (%) 117 (39) 40 39 0.86 0.70
Hemodynamic measures
Systolic BP (mmHg) 133620 134620 131619 0.21 0.33
Diastolic BP (mmHg) 76610 77611 76610 0.37 0.34
Pulse pressure 57616 58616 56616 0.25 0.44
Mean arterial pressure 95612 96612 94611 0.22 0.28
Lab values
LDL-C (mg/dl) 111637 112639 109633 0.52 0.58
HDL (mg/dl) 53613 53613 53613 0.99 0.82
Triglycerides (mg/dl)
(medians[IQR])*
113 [72, 169] 122 [76, 169] 96 [70, 172] 0.37 0.55*
Total cholesterol 191643 192644 191641 0.92 0.94
Fasting blood glucose 104639 103638 107640 0.33 0.31
Creatinine (mg/dl) 0.7960.18 0.8060.19 0.7860.16 0.48 0.61
Hemoglobin (g/dl) 13.061.4 13.161.4 12.961.3 0.25 0.21
Medication use
Any antihypertensive use (%) 167/283 (59) 60 57 0.62 0.74
Any lipid lowering meds (%) 52/297 (18) 19 15 0.41 0.45
Ever HRT use (%) 160/293 (55) 56 52 0.42 0.55
Current HRT use (%) 116/294 (39) 40 38 0.70 0.83
Statins (%) 39/297 (13) 13 14 0.86 0.77
ACE inhibitors (%) 51/269 (19) 18 20 0.66 0.51
Beta blockers (%) 89/297 (30) 29 31 0.67 0.65
Aspirin (%) 138/296 (47) 49 42 0.23 0.27
Diuretics (%) 63/297 (21) 19 24 0.25 0.19
Other variables
CAD severity score (medians[IQR])*5.0 [5.0, 7.5] 5.0 [5.0, 7.5] 5.0 [5.0, 6.2] 0.57 0.72*
Functional capacity (DASI) 21.4614.9 22.6615.3 19.7614.2 0.11 0.10
Unstable angina past 6 wks 74/266 (28) 27 29 0.72 0.81
cTFC = corrected TIMI frame count; HS educ = High School education; BMI = body mass index; Hx = history; HRT = hormone replacement therapy; CAD = coronary
artery disease.
*Because of skewed distribution, medians [interquartile ranges] are given and Log transformations were used to estimate the age-adjusted p-values.
**For frequencies, where there were missing values, the statistic given is: no. with the condition/no. available (%).
doi:10.1371/journal.pone.0096630.t001
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an ACE-I for those with more severe angina. Additionally, follow-
up blood pressure for our current cohort was higher than the
baseline blood pressure in those patients randomized to an ACE
inhibitor in the Pauly et al trial [22]. We suspect that baseline ACE
inhibitor use in our current cohort is likely a marker of more
advanced vascular disease, which may have contributed to an
increased risk of angina hospitalization. In this pilot investigation,
cTFC was not associated with a statistically significant increase in
risk of major events (myocardial infarction, heart failure, stroke, or
all-cause death), CV events, all-cause mortality, or CV mortality.
Studies comparing TFC to more invasive measures of coronary
vasomotion (endothelial or non-endothelial dependent macro- or
microvascular function) have provided various results. Many
studies have shown that TFC does correlate with measures of
coronary vasomotion [23–26], whereas others have shown no
correlation of TFC and coronary flow reserve [27]. Most of these
studies were small. Some of these studies included patients with
obstructive CAD and others excluded patients with obstructive
CAD. Some of these studies determined the change in TFC from
baseline to the TFC at hyperemia, and correlated this change in
TFC with measures of coronary vasomotion, whereas some looked
at only the correlation of TFC at rest with measures of coronary
vasomotion. Therefore, it remains unclear if TFC at rest can
replace evaluation of coronary vasomotion with more traditional
methods. Because TFC at rest does not require instrumentation of
the coronary artery nor vasoactive medication, future study
evaluating the correlation of TFC at rest with CFR determined
after administration of adenosine and change in coronary artery
diameter and coronary blood flow after acetylcholine in patients
without obstructive CAD remains warranted.
The major limitation of our study is the relatively small number
of major events. Because of the small number of events, the
current analysis provides low statistical power to find a relationship
between TFC and major events. In order to have appropriate
power to determine if there is a significant difference in major
event rates between TFC groups, we estimate that we would need
approximately 880 patients.
In conclusion, in women with signs and symptoms of ischemia
but no obstructive CAD, resting cTFC provides independent
prediction of hospitalization for angina. Larger studies are
required to determine if resting cTFC is predictive of major
events in patients without obstructive coronary artery disease.
Figure 2. Survival free of hospitalization for angina according
to TIMI Frame Count groups. Kaplan-Meier analysis of survival free
of hospitalization for angina.
doi:10.1371/journal.pone.0096630.g002
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